Hemochromatosis and Diabetes Mellitus
Authors: Robert A. Hegele, Stewart B. Harris, Bernard Zinman
Journal: Annals of Internal Medicine (1998)

Letters1 October 1998Hemochromatosis and Diabetes MellitusRobert A. Hegele, MD, Stewart B. Harris, MD, and Bernard Zinman, MDRobert A. Hegele, MDUniversity of Western Ontario; London, Ontario N6A 5K8, CanadaUniversity of Toronto; Toronto, Ontario M5G 1X5, CanadaSearch for more papers by this author, Stewart B. Harris, MDUniversity of Western Ontario; London, Ontario N6A 5K8, CanadaUniversity of Toronto; Toronto, Ontario M5G 1X5, CanadaSearch for more papers by this author, and Bernard Zinman, MDUniversity of Western Ontario; London, Ontario N6A 5K8, CanadaUniversity of Toronto; Toronto, Ontario M5G 1X5, CanadaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-7-199810010-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Hemochromatosis occurs in persons who are homozygous for the C282Y mutation in the HFE gene [1]. Conte and colleagues [2] reported that in patients with type 2 diabetes mellitus, the odds ratio of hemochromatosis was 7.3 (95% CI, 1.3 to 41.9), although the absolute prevalence of hemochromatosis was low [2]. They suggested that screening for hemochromatosis may be beneficial for patients with type 2 diabetes.The Sandy Lake aboriginal reserve in Northern Ontario, Canada, has the world's third highest population prevalence of type 2 diabetes [3]. To determine whether the HFE C282Y mutation was associated with this ...References1. Cuthbert JA. Iron, HFE and hemochromatosis update. J Invest Med. 1997; 45:518-29. Google Scholar2. Conte D, Manachino D, Colli A, Guala A, Aimo G, Andreoletti M, et al. Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Ann Intern Med. 1998; 128:370-3. Google Scholar3. Harris SB, Gittelsohn J, Hanley AJ, Barnie A, Wolever TM, Gao J, et al. The prevalence of NIDDM and associated risk factors in native Canadians. Diabetes Care. 1997; 20:185-97. Google Scholar4. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997; 34:275-8. Google Scholar Author, Article, and Disclosure InformationAuthors: Robert A. Hegele, MD; Stewart B. Harris, MD; Bernard Zinman, MDAffiliations: University of Western Ontario; London, Ontario N6A 5K8, CanadaUniversity of Toronto; Toronto, Ontario M5G 1X5, Canada PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThree Authors ReplyHemochromatosis Gene (HFE) Polymorphisms and Risk of Type 2 Diabetes Mellitus: A Meta-AnalysisGenes, environment and Oji-Cree type 2 diabetesGenes and environment in type 2 diabetes and atherosclerosis in aboriginal canadiansA prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) studyPeroxisome Proliferator-Activated Receptor-γ2 P12A and Type 2 Diabetes in Canadian Oji-Cree*The Hepatic Nuclear Factor-1α G319S Variant Is Associated with Early-Onset Type 2 Diabetes in Canadian Oji-Cree1Genetic prediction of coronary heart disease: Lessons from Canada 1 October 1998Volume 129, Issue 7Page: 587KeywordsAllelesDiabetes mellitusGlobal healthGlucose intoleranceHemochromatosisOdds ratioType 2 diabetes ePublished: 15 August 2000 Issue Published: 1 October 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...